NASDAQ:CNTN Hillstream Biopharma (CNTN) Stock Price, News & Analysis $2.11 +0.03 (+1.44%) Closing price 10/9/2026 04:00 PM EasternExtended Trading$2.12 +0.01 (+0.24%) As of 10/9/2026 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsInsider TradesNews and TrendsSEC FilingsShort Interest About Hillstream Biopharma Stock (NASDAQ:CNTN) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Hillstream Biopharma alerts:Sign Up Key Stats Today's Range$2.09▼$2.2050-Day Range$1.86▼$2.6952-Week Range$1.75▼$6.89Volume721,433 shsAverage Volume934,821 shsMarket Capitalization$168.13 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingSell Company Overview Hillstream Biopharma, Inc. is a clinical-stage biotechnology company focused on developing novel treatments for cancer. The company’s research centers on ferroptosis, a form of regulated cell death that may offer a way to selectively target tumor cells, including cancer cells that have developed resistance to existing therapies. Hillstream’s pipeline has included HSB-1216, an investigational ferroptosis-inducing therapy being evaluated for potential use in solid tumors. The company has also pursued additional preclinical oncology programs designed to address treatment-resistant cancers. Its products remain investigational and require successful clinical development and regulatory review before they can be marketed. Hillstream Biopharma was founded to advance therapies based on discoveries in cancer biology and has operated as a U.S.-based biotechnology company. Information about its commercial operations and geographic reach is limited because the company remains focused primarily on research and clinical development rather than selling approved products.AI Generated. May Contain Errors. Read More Hillstream Biopharma Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks8th Percentile Overall ScoreCNTN MarketRank™: Hillstream Biopharma scored higher than 8% of companies evaluated by MarketBeat, and ranked 806th out of 853 stocks in the finance sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion0.7 / 5Analyst RatingSell Consensus RatingHillstream Biopharma has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no strong buy ratings, no buy ratings, no hold ratings, and 1 sell rating.Amount of Analyst CoverageHillstream Biopharma has only been the subject of 1 research reports in the past 90 days.Read more about Hillstream Biopharma's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Hillstream Biopharma is -4.22, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Hillstream Biopharma is -4.22, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioHillstream Biopharma has a P/B Ratio of 0.19. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted10.15% of the float of Hillstream Biopharma has been sold short.Short Interest Ratio / Days to CoverHillstream Biopharma has a short interest ratio ("days to cover") of 7.08.Change versus previous monthShort interest in Hillstream Biopharma has recently increased by 15.42%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldHillstream Biopharma does not currently pay a dividend.Dividend GrowthHillstream Biopharma does not have a long track record of dividend growth. News and Social Media3.9 / 5News Sentiment1.28 News SentimentHillstream Biopharma has a news sentiment score of 1.28. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.62 average news sentiment score of Finance companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Hillstream Biopharma this week, compared to 1 article on an average week.Search InterestOnly 2 people have searched for CNTN on MarketBeat in the last 30 days. This is a decrease of -33% compared to the previous 30 days.MarketBeat Follows1 people have added Hillstream Biopharma to their MarketBeat watchlist in the last 30 days. Company Ownership0.1 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Hillstream Biopharma insiders have not sold or bought any company stock.Percentage Held by Insiders3.34% of the stock of Hillstream Biopharma is held by insiders.Percentage Held by Institutions1.16% of the stock of Hillstream Biopharma is held by institutions.Read more about Hillstream Biopharma's insider trading history. Receive CNTN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Hillstream Biopharma and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. CNTN Stock News HeadlinesHillstream Biopharma (NASDAQ:CNTN) Shares Down 8% - Time to Sell?October 9 at 2:21 AM | americanbankingnews.comCanton Strategic Holdings, Inc. Releases Second Quarter 2026 Financial and Operational ResultsAugust 14, 2026 | prnewswire.comIran War Shock: What I Was Told In That Private MeetingYou’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially the reasons why we’re bombing the country.October 10 at 1:00 AM | Banyan Hill Publishing (Ad)Canton Strategic: Highly Intriguing Blockchain Treasury With Tangible RisksAugust 6, 2026 | seekingalpha.comThree New Directors Elected to the Board of Canton Strategic Holdings, Inc.July 28, 2026 | prnewswire.comCanton Strategic Holdings, Inc. Announces Sale of Gravitas Life Sciences, LLCJuly 23, 2026 | prnewswire.comCanton Strategic Holdings, Inc. Delivers Second Quarter Canton Network Ecosystem UpdateJuly 17, 2026 | prnewswire.comCanton Strategic Holdings, Inc. Announces Launch of Locking Service to Support Network Infrastructure ProvidersJune 23, 2026 | prnewswire.comSee More Headlines CNTN Stock Analysis - Frequently Asked Questions How have CNTN shares performed this year? Hillstream Biopharma's stock was trading at $4.66 on March 10, 2026. Since then, CNTN shares have decreased by 54.7% and is now trading at $2.11. How do I buy shares of Hillstream Biopharma? Shares of CNTN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Today10/10/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Yellow Zone (5m+) 1-Year History Oct 25 Jan 26 Apr 26 Jul 26 Oct 26 CNTN's financial health is in the Yellow zone, according to TradeSmith. CNTN has been in this zone for over 5 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorFinance Industry Financial Services Sub-IndustryMulti-Sector Holdings Current SymbolNASDAQ:CNTN CIK1861657 Webwww.cantonstrategic.com Phone(302) 743-2995FaxN/AEmployees12Year FoundedN/AProfitability EPS (Trailing Twelve Months)($0.50) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$35.92 million Net MarginsN/A Pretax Margin-7,641.51% Return on Equity-20.06% Return on Assets-15.90% Debt Debt-to-Equity RatioN/A Current Ratio15.70 Quick Ratio15.70 Sales & Book Value Annual Sales$1.50 million Price / Sales112.39 Cash FlowN/A Price / Cash FlowN/A Book Value$10.92 per share Price / Book0.19Miscellaneous Outstanding Shares79,681,000Free Float77,020,000Market Cap$168.13 million OptionableN/A Beta1.46 7 Stocks to Buy Before the Robotics RevolutionRobotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.Get This Free Report This page (NASDAQ:CNTN) was last updated on 10/10/2026 by MarketBeat.com Staff. From Our PartnersA letter from Shannon StansberryPorter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down ye...Porter & Company | SponsoredThe only 5 stocks that matterSpaceX's IPO reportedly minted 4,400 new millionaires, and OpenAI is said to be eyeing a 1 trillion dollar IPO...TradeSmith | SponsoredIran War Shock: What I Was Told In That Private MeetingYou’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...Banyan Hill Publishing | SponsoredNew Chip takes minutes, not daysGeorge Gilder believes today's AI data centers could become tomorrow's typewriters - replaced by a single wafe...Eagle Publishing | SponsoredTrump goes "all-in" on Grand Canyon energy breakthroughA drilling crew near the Grand Canyon uncovered a clean energy well producing nearly eight times the output of...Behind the Markets | SponsoredA simple options setup that cuts through the noiseIan Cooper says most options traders overcomplicate the process, juggling countless indicators, strategies, an...TradeWins | SponsoredThis free guide explains options the way they should be taughtMost options educators jump straight into Greeks, spreads, and implied volatility - losing beginners before th...Base Camp Trading | SponsoredSmall Colorado Company (Backed by Sam Altman) Could Save U.S. Power GridA small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Hillstream Biopharma Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Hillstream Biopharma With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
